Türk Börü Ü.Duman A.Bölük C.Coşkun Duman S.Taşdemir M.2024-07-122024-07-1220170025-797410.1097/MD.0000000000008133https://dx.doi.org/10.1097/MD.0000000000008133https://hdl.handle.net/20.500.12415/8340Background: Botulinum toxin type-A (BTX-A) has been successfully utilized to treat trigeminal neuralgia. In this study, through the use of a new technique, the efficacy of the injection of BTX-A to the maxillary and mandibular nerves was evaluated. Methods: A total of 27 patients were injected with 100 Units of BTX-A to the maxillary and mandibular nerves. Visual analogue scale score and pain frequency were assessed before treatment and at the first week, second month, and sixth month after treatment. Patients with ?50% reduction in mean pain score at the second and sixth month were defined as responders. Results: A total of 27 patients were included in the study. BTX-A significantly reduced pain intensity and pain attack frequency at the first week, second month, and sixth month after treatment. At the second month, 74.1% of patients, at the sixth month, 88.9% of patients responded to treatment. Forty-four percent of patients did not experience any pain at the sixth month. The mean recurrence period was 87.7±20.4. BTX-A was well tolerated and showed few treatment-related adverse events. Conclusion: Injection to the maxillary and mandibular roots seems to be a highly effective method. In the event of recurrence, after each injection, the pain severity and attack frequency decreased. Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc.eninfo:eu-repo/semantics/openAccessbotulinum toxintreatmenttrigeminal neuralgiaArticle3928953646Q396